Based on these results, neratinib was evaluated in the adjuvant setting in the phase III, randomized, placebo-controlled ExteNET study, which assessed the benefit of addition of 1 year of adjuvant neratinib after standard chemotherapy and trastuzumab in patients with early-stage, high-risk HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.